Featured Story | By Annalee Armstrong Vertex has boosted an agreement with CRISPR Therapeutics to $900 million upfront as the companies race to beat bluebird bio to the market with a new gene editing therapy for sickle cell disease and beta-thalassemia called CTX001. read more |
| |
|---|
|
Top Stories By Amirah Al Idrus As Gossamer Bio seeks partners to keep its failed DP2 inhibitor afloat, the company is losing its top scientist. Luisa Salter-Cid, Ph.D., the Bristol Myers Squibb veteran who joined Gossamer in September 2018, will leave on April 30, making way for Laura Carter, Ph.D. read more By Amirah Al Idrus Just weeks after handing full control of its Takeda-partnered epilepsy program back to the Japanese pharma, Ovid Therapeutics is pulling the plug on its lead program, OV101, a treatment that was under development for Angelman syndrome and Fragile X syndrome. Now, the company’s focus turns to its earlier-stage pipeline. read more Sponsored By: Catalent Cell & Gene Therapy Working with the right integrated partner can help ease increasingly common problems with scale, access to high-demand raw material, viral vector production and quality requirements. read more By Ben Adams Using the tailwinds of the pandemic, Forbion has raised a healthy €360 million ($428 million) to invest in a range of late-stage European life sciences companies. read more By Ben Adams A midstage test of KalVista Pharmaceuticals’ hereditary angioedema hopeful KVD824 has been slapped with an FDA clinical hold as it demands more preclinical data and changes to its protocol. read more By Andrea Park The world may not yet have the technology to turn back time, but Virta Health is hoping its telehealth platform will do the trick for users with Type 2 diabetes. read more By Kevin Dunleavy With the COVID-19 vaccine landscape shifting in favor of mRNA shots, Bernstein analyst Ronny Gal predicts $24 billion in sales for Pfizer and $14 billion for Moderna this year. The prediction comes amid setbacks for the Johnson & Johnson and AstraZeneca vaccines on both sides of the Atlantic. read more Resources Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process intesification Sponsored By: August Bioservices How has COVID-19 impacted CRO/CDMO customer (dis)satisfaction and outsourcing decisions for pharma and biotech companies in 2021 and beyond? Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule Sponsored by: PerkinElmer Informatics Discover the benefits of a cloud-native ELN that delivers better performance, security, connectivity, total cost of ownership PLUS sub-second search results through even the largest data volumes. Sponsored by: PulsePoint Access this guide for the latest insights into how marketers can use data, technology, and personalized messaging to build vaccine confidence and drive successful immunization efforts. Sponsored By: Within3 We enable virtual work — offering over-time sessions where participants are more focused, insights are more diverse and business goals are met. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: TAC Roche has inked a $1.8 billion, all-cash deal for GenMark Diagnostics, to acquire its molecular tests designed to screen patient samples for multiple infections simultaneously. Sponsored By: Remarque Systems Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. Sponsored By: Culture Biosciences Find out how upstream bioprocess scientists can use Culture Biosciences’ bioreactor system and real-time data visualizations to get faster insights and get their product to market more quickly. Sponsored By: BC Platforms Those wishing to unlock RWD’s true value must have access to a variety of data sources/types and the technological capabilities to use the data to uncover meaningful insights. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: Catalent Autologous cell therapies have seen propelled growth since 2017, with the spotlight on the first FDA approval of a chimeric antigen receptor (CAR) T cell immunotherapy, Kymriah® (tisagenlecleucel), for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. | 
